Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: Studies with cyclosporine A
Journal Title: The AAPS Journal - Year 2002, Vol 4, Issue 4
Abstract
Lipoproteins are a heterogeneous population of macromolecular aggregates of lipids and proteins that are responsible for the transport of lipids through the vascular and extravascular fluids from their site of synthesis or absorption to peripheral tissues. Lipoproteins are involved in other biological processes as well, including coagulation and tissue repair, and serve as carriers of a number of hydrophobic compounds within the systemic circulation. It has been well documented that disease states (eg, AIDS, diabetes, cancer) significantly influence circulating lipoprotein content and composition. Therefore, it appears possible that changes in the lipoprotein profile would affect not only the ability of a compound to associate with lipoproteins but also the distribution of the compound within the lipoprotein subclasses. Such an effect could alter the pharmacokinetics and pharmacological action of the drug. This paper reviews the factors that influence the interaction of one model hydrophobic compound, cyclosporine A, with lipoproteins and the implications of altered plasma lipoprotein concentrations on the pharmacological behavior of this compound.
Authors and Affiliations
Kishor M. Wasan, Manisha Ramaswamy, Mona Kwong, Kathy D. Boulanger
Keywords
Related Articles
- EP ID EP682029
- DOI 10.1208/ps040430
- Views 99
- Downloads 0
Use of anatomical and kinetic models in the evaluation of human food additive safety
Toxicological testing in animals is relied upon as a surrogate for clinical testing of most food additives. Both animal and human clinical test results are generally available for direct additives when high levels of exp...
Sequential Bioequivalence Approaches for Parallel Designs
The online version of this article (doi:10.1208/s12248-014-9571-1) contains supplementary material, which is available to authorized users.
Are Physiologically Based Pharmacokinetic Models Reporting the Right Cmax? Central Venous Versus Peripheral Sampling Site
The online version of this article (doi:10.1208/s12248-015-9796-7) contains supplementary material, which is available to authorized users.
Reproductible production of a PEGylated dual-acting peptide for diabetes
A pEGylated glucagon-like peptide-1 (GLP-1) agonist and glucagon antagonist hybrid peptide was engineered as a potential treatment for type 2 diabetes. To support preclinical development of this PEGylated dual-acting pep...
Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage
The online version of this article (doi:10.1208/s12248-016-9898-x) contains supplementary material, which is available to authorized users.